MabVax Therapeutics Holdings Inc buy melinda
Start price
27.06.17
/
50%
?1.35
Target price
19.12.17
€3.25
Performance (%)
-45.34%
End price
19.12.17
€0.74
Summary
This prediction ended on 19.12.17 with a price of €0.74. The BUY prediction by melinda for MabVax Therapeutics Holdings Inc performed very badly with a performance of -45.34%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| MabVax Therapeutics Holdings Inc | - | - | - | - |
| iShares Core DAX® | -1.741% | 5.666% | 7.839% | 50.715% |
| iShares Nasdaq 100 | 2.815% | 11.547% | 36.610% | 102.822% |
| iShares Nikkei 225® | -0.109% | 9.654% | 45.650% | 64.795% |
| iShares S&P 500 | 0.966% | 7.240% | 26.969% | 70.251% |
Comments by melinda for this prediction
In the thread MabVax Therapeutics Holdings Inc diskutieren
Phase-1-Studie pancreas.côlon.poumon
Mabvax Therapeutics beginnt Patienten Dosierung im Test Radioimmun MVT-1075
27. Juni (Reuters) - Mabvax Therapeutics Holdings Inc: Mabvax Therapeutics beginnen Patientendosierung in der klinischen Phase - 1 - Studie mit Radioimmuntherapie MVT-1075 zur Behandlung von Bauchspeicheldrüsenkrebs, Dickdarm und Lunge. Das Unternehmen rechnet damit, bis Ende 2017 für MVT-1075 Zwischenergebnisse zu berichten.
(Vom Mitglied beendet)